The homeostatic chemokine CXCL13 is constitutively expressed in secondary lymphoid tissue and known to initiate lymphoid neogenesis when expressed aberrantly in mice. CXCL13 has also been detected in chronic inflammation associated with human lymphoid neogenesis, suggesting a pathogenic role. Follicular dendritic cells are generally considered to be the major source of CXCL13 both in normal and aberrant lymphoid tissue. CXCL13 has been the exclusive ligand for CXCR5, which initiates chemotaxis toward an increasing gradient in vitro and to B cell zones in lymph nodes that express CXCL13. More recently, CXCR5 expression has also been shown in DN T cells in mice, a subset of CD4 follicular Th cells, and some tonsillar CD4+ and CD25+ Tregs in humans.
Product Name- Recombinant Human BCA-1 (CXCL13)
Aliases- BCA1, BLC, B cell Attracting Chemokine-1, CXCL13, C-X-C motif chemokine 13
Formulation- Lyophilized from a 0.2 µm filtered solution in PBS,100 µm NaCl, pH 7.5
Endotoxin Level- <1.0 EU/µg of recombinant protein as determined by the LAL method.
Storage Condition- The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at +2° to +8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.